Following the release of a drug, the FAERS database collects adverse events reports from providers and patients that are witnessed in-market (i.e., in the real world practice of medicine rather than during a clinical trial or drug testing process)
It is performed internally, not by independent third-party laboratories
[PubMed] Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, Kobayashi T, Nogami A, Higurashi T, Kato S, Hosono K, Saito S, Nakajima A (2021) Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: A retrospective nationwide claims database study in Japan
What is the typical cycle length for L-Carnitine, and can I extend it
Originally used for managing type 2 diabetes, Semaglutide GLP-1 is a glucagon-like peptide-1 (GLP-1) receptor agonist